Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research

Comparative effectiveness research (CER) has been heralded as a way to reduce health-care costs by determining which treatments provide the most benefit for the largest number of patients. This report warns that by choosing "winners and losers," CER drug trials may leave patients who best respond to the "losing" drug without coverage.

The report, conducted by researchers Tomas Philipson and Eric Sun of the Manhattan Institute's Project FDA, examines a CER trial for antipsychotic drugs in the Medicaid program and finds that applying restrictive reimbursement for "losing" drugs could actually reduce patient health and increase health-care costs. By limiting coverage for more expensive drugs that benefit patients outside the average, the authors find that worsened patient health would increase health-care costs by $1.3 billion, outweighing the Medicaid savings.

Dr. Philipson authored a related paper on this topic, "The Impact of Comparative Effectiveness Research on Health and Health Care Spending," that was published in the Journal of Health Economics website.

Blog Post

Tackling Data Access at Health Datapalooza

By Jennifer Graff, PharmD, NPC VP for Comparative Effectiveness ResearchWe’re looking forward to participating in Health Datapalooza next week, which...
Newsletter Volume

E.V.I.dently: April 2016

MessageValue Assessment Through a Broader, Patient-Focused LensNPC has developed “Guiding Practices for Patient-Centered Value Assessment” to help...
Blog Post

Bundled Payments: Opportunities and Challenges

As use of bundled payments increases, how do health system stakeholders minimize the risk of unintended consequences and maximize chances this...
Commentary and Testimony Page

NPC Comments on Revised PCORI Methodology Standards

March 28, 2016Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036 Dr. Robin...
Press Release

New Study Examines Risk-Sharing Agreements Between Pharmaceutical Manufacturers and Payers

(Washington, DC, September 16, 2015)—A newly released study has found that risk-sharing agreements (RSAs) between pharmaceutical companies and health...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Press Release

NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making

(Washington, DC, March 26, 2015)—A new survey of health care stakeholders reveals continued optimism that comparative effectiveness research (CER)...
Commentary and Testimony Page

NPC Comments on Revised PCORI Methodology Standards

March 28, 2016Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036 Dr. Robin...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
YouTube Videos

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

This one-hour webinar highlights the results of NPC's annual survey of comparative effectiveness research (CER) stakeholders and includes a panel...
YouTube Videos

NHC's Boutin: Measuring Health Outcomes & Patient Aspirations

Marc Boutin, JD, CEO, National Health Council, emphasizes the need to ensure that we are integrating a patient’s perspective at the time that we are...
YouTube Videos

NHC's Boutin: Incorporating Patient Aspirations With Medical Outcomes

Marc Boutin, JD, CEO, National Health Council, says while medical outcomes are critical to patients with chronic illnesses, it's also important for...
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
Blog Post

Tackling Data Access at Health Datapalooza

By Jennifer Graff, PharmD, NPC VP for Comparative Effectiveness ResearchWe’re looking forward to participating in Health Datapalooza next week, which...
Blog Post

Bundled Payments: Opportunities and Challenges

As use of bundled payments increases, how do health system stakeholders minimize the risk of unintended consequences and maximize chances this...
Blog Post

ASCO’s Clinical Pathways Recommendations and Remaining Challenges

The American Society of Clinical Oncology (ASCO) today released its “policy statement on clinical pathways in oncology,” which acknowledges the...
Blog Post

Key Considerations for Cost Effectiveness Thresholds

While putting a price tag on the value of health care services and the life years gained is common in countries including the United Kingdom, Canada...
cersurvey16

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's sixth annual survey of stakeholder views on comparative effectiveness research (CER) and the...

What Contributes Most to High Health Care Costs?

A small segment of the population—often the sickest

Standards and Guidelines for Observational Studies: Quality Is in the Eye of the Beholder

The lack of observational study standard/guideline agreement may contribute to variation in study...
  •  
  • 1 of 55
  • >